Applied Finance Capital Management LLC Acquires 3,190 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Applied Finance Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 16.1%, acquiring an additional 3,190 shares during the second quarter, bringing the total to 22,983 shares valued at approximately $12.06 million.
• The stock has received mixed ratings from analysts, with a consensus rating of Moderate Buy and a target price averaging around $817.88.
• In its latest earnings report, Regeneron Pharmaceuticals exceeded analyst expectations by reporting $12.89 earnings per share, significantly higher than the anticipated $8.43.

Applied Finance Capital Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,983 shares of the biopharmaceutical company's stock after acquiring an additional 3,190 shares during the quarter. Applied Finance Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $12,066,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. E Fund Management Hong Kong Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management grew its position in Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth about $27,000. Saudi Central Bank bought a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Finally, Colonial Trust Advisors purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Sanford C. Bernstein raised their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 27th. Redburn Atlantic raised Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a research note on Friday, August 1st. Finally, Truist Financial cut their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $817.88.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $569.17 on Friday. The firm has a market capitalization of $60.33 billion, a P/E ratio of 14.34, a PEG ratio of 1.85 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,013.09. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The business has a fifty day moving average price of $574.34 and a 200-day moving average price of $563.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period in the previous year, the company posted $11.56 EPS. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.